Quick Answer
Sage Cognition Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: In this edition of the Huntington's Disease Clinical Trials Update, we expand on the launch of the phase II/III clinical trial of SKY-0515 from Skyhawk Therapeutics and the phase I/II clinical trial of SPK-10001 from Spark Therapeutics.
Key Takeaways
- 01In this edition of the Huntington's Disease Clinical Trials Update, we expand on the launch of the phase II/III clinical trial of SKY-0515 from Skyhawk Therapeutics and the phase I/II clinical trial of SPK-10001 from Spark Therapeutics. [Farag M (2025)]
- 02We also report positive topline data from uniQure's phase I/II clinical trial of AMT-130 after 36 months of follow-up. [Farag M (2025)]
The current Migaku evidence database contains 2 reusable source documents for Sage Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation.
- In this edition of the Huntington's Disease Clinical Trials Update, we expand on the launch of the phase II/III clinical trial of SKY-0515 from Skyhawk Therapeutics and the phase I/II clinical trial of SPK-10001 from Spark Therapeutics. [Farag M (2025); evidence level 2]
- We also report positive topline data from uniQure's phase I/II clinical trial of AMT-130 after 36 months of follow-up. [Farag M (2025); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources